Clinical Trial Update: Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating RO4929097 (gamma-secretase/Notch pathway inhibitor) with cisplatin, vinblastine, and temozolomide in recurrent or metastatic melanoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Melanoma

Drugs mentioned

• CISPLATIN (cisplatin)
• RO4929097 (RO4929097)
• Temozolomide (Temozolomide)
• Vinblastine (vinblastine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Skin Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-10-18